Pay in 4 interest-free payments of $7.31 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Evaluating Telehealth Weight Loss Options: What to Consider When Choosing a Platform Key Factors to Evaluate in Any GLP-1 Telehealth Program When considering telehealth options for GLP-1 weight loss medications, according to healthcare consumer guidance and medical best practices, members should evaluate multiple factors: Medical Oversight Quality : Are services provided by licensed healthcare providers (MD, DO, NP, PA)
Frequently Booked Together Questions
Semaglutide is a single-receptor (GLP-1) agonist, tirzepatide is a dual GLP-1/GIP agonist, and retatrutide is a triple GLP-1/GIP/glucagon agonist
Eli Lilly is developing a pre-filled pen for retatrutide, similar to the Mounjaro pen for tirzepatide
Some individuals have more responsive GLP-1 receptors in their hypothalamus (the brain region controlling hunger), leading to earlier appetite suppression
In research, GLP1-S both mimics and amplifies GLP-1s physiological effects, making it highly relevant in studies exploring: Glucose regulation Appetite control and energy balance Obesity and metabolic disorders Appetite Regulation GLP1-S influences appetite control centers in the brain, particularly the hypothalamus, which plays a key role in regulating hunger and satiety[1]
